HD18 for Advanced Stages in Hodgkins Lymphoma

Conditions

Hodgkins Lymphoma

Keywords

Hodgkin lymphoma, PET, advances stages, Rituximab

Brief summary

This study is designed to test: 1. in patients with negative positron-emission tomography (PET) after 2 cycles of BEACOPPesc chemotherapy: whether the number of cycles can be reduced without compromising progression free survival (PFS) (2 further cycles vs. 6 further cycles) 2. for patients with positive PET after 2 cycles: whether intensifying BEACOPPesc chemotherapy by adding Rituximab improves PFS.

Simon Leiders, Dominic Ufton, Helen Kaul, Jasmin Weindler, Johannes Rosenbrock et al. (18 authors)

Blood Advances2026-06-30

10.1182/bloodadvances.2026019712

Association between metabolic tumor burden and health-related quality of life in patients with classic Hodgkin lymphoma.

Lommen M, Weindler JJ, Jablonski J, Rosenbrock J, Borchmann P, Behringer K, Roth KS, Ufton D, Dietlein M, Kobe C, Ferdinandus J.

2025-10-11

10.1007/s00259-025-07569-5

Metabolic Tumor Volume after Two Cycles of Chemotherapy in Patients Treated for Advanced-Stage Hodgkin Lymphoma: Analysis of the German Hodgkin Study Group Phase III HD18 and HD21 Trials

Justin Ferdinandus, Helen Kaul, Gundolf Schneider, Michael Fuchs, Hans Theodor Eich et al. (13 authors)

Blood2024-11-055 citations

10.1182/blood-2024-210791

PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.

Kreissl S, Goergen H, Buehnen I, Kobe C, Moccia A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Dietlein M, Engert A, Borchmann P, German Hodgkin Study Group.

2021-06-0142 citations

10.1016/s2352-3026(21)00101-0

Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma.

Kobe C, Goergen H, Baues C, Kuhnert G, Voltin CA, Zijlstra J, Hoekstra O, Mettler J, Drzezga A, Engert A, Borchmann P, Dietlein M.

2018-08-3031 citations

10.1182/blood-2018-05-852129

Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18

Conrad‐Amadeus Voltin, Helen Goergen, Christian Baues, Michael Fuchs, Jasmin Mettler et al. (14 authors)

Annals of Oncology2018-07-1356 citations

10.1093/annonc/mdy250

Early Interim PET in Patients with Advanced-Stage Hodgkin's Lymphoma Treated within the Phase 3 GHSG HD18 Study

Peter Borchmann, Helen Goergen, Carsten Kobe, Andreas Lohri, Richard Greil et al. (20 authors)

Blood2017-12-076 citations

10.1182/blood.v130.suppl_1.737.737

PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.

Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Engert A.

2017-10-20233 citations

10.1016/s0140-6736(17)32134-7

Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP<sub>escalated</sub> alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.

Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, Markova J, Feuring-Buske M, Meissner J, Dührsen U, Ostermann H, Keller U, Maschmeyer G, Kuhnert G, Dietlein M, Kobe C, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Engert A.

2017-02-2265 citations

10.1016/s1470-2045(17)30103-1

Addition of Rituximab to BEACOPPescalated to Improve the Outcome of Early Interim PET Positive Advanced Stage Hodgkin Lymphoma Patients: Second Planned Interim Analysis of the HD18 Study.

Peter Borchmann, Heinz Haverkamp, Andreas Lohri, Stefanie Kreissl, Richard Greil et al. (17 authors)

Blood2014-12-0617 citations

10.1182/blood.v124.21.500.500

Interventions

DRUGRituximab

addition of Rituximab to BEACOPP escalated

DRUGBEACOPP escalated

chemotherapy with BEACOPP escalated

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

No

Inclusion criteria

* Hodgkin Lymphoma (histologically proven) * CS (PS) IIB with one or both of the risk factors: * bulky mediastinal mass (\> 1/3 of maximum transverse thorax diameter) * extranodal involvement * CS (PS) III, IV * Written informed consent

Exclusion criteria

* Leucocytes \< 3000/µl * Platelets \< 100000/µl * Hodgkin´s lymphoma as composite lymphoma * Activity index (WHO) \< grade 2

Design outcomes

Primary

Measure	Time frame
Progression Free Survival	5 years

Secondary

Measure	Time frame
Overall Survival	5 years
acute toxicity	5 years
late toxicity	5 years
CR-rate	5 years

Countries

Germany

Outcome results

None listed